FIELD: medicine.
SUBSTANCE: invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.
EFFECT: method enables reducing dyspepsia events and encephalopathy manifestations.
5 ex, 3 tbl, 1 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING PATIENTS WITH HEPATIC CIRRHOSIS | 2012 |
|
RU2509566C1 |
METHOD OF DIAGNOSING HEPATIC ENCEPHALOPATHY OF LATENT STAGE IN PATIENTS WITH CHRONIC LIVER DISEASES | 2011 |
|
RU2468745C1 |
METHOD OF TREATING PATIENTS SUFFERING FROM FIRST STAGE CHOLELITHIASIS | 2012 |
|
RU2519198C2 |
METHOD OF TREATING PATIENTS WITH INTESTINAL DYSBACTERIOSIS | 2009 |
|
RU2400235C1 |
METHOD FOR PREDICTION OF FATAL OUTCOMES IN PATIENTS SUFFERING VIRAL OR ALCOHOLIC CIRRHOSIS | 2011 |
|
RU2465818C1 |
METHOD OF TREATING CEREBRAL OEDEMA IN PATIENTS SUFFERING FROM CHRONIC LIVER DISEASES | 2014 |
|
RU2539139C1 |
METHOD OF TREATING PATIENTS WITH INTESTINAL DISBACTERIOSIS | 2014 |
|
RU2571495C1 |
METHOD OF PROPHYLAXIS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHOLELITHIASIS AFTER LAPAROSCOPIC CHOLECYSTECTOMY | 2017 |
|
RU2657838C1 |
METHOD OF HUMAN VISCERA MEDICAL TREATMENT | 2004 |
|
RU2325904C2 |
MEDICATION FOR TREATING INTESTINAL DYSBIOSIS IN PATIENTS WITH CHRONIC CRYPTOGENIC HEPATITIS | 2009 |
|
RU2411955C1 |
Authors
Dates
2012-09-27—Published
2011-04-11—Filed